Âé¶¹´«Ã½É«Ç鯬

Journal News

Plasma membrane is no barrier to free fatty acid

Nathalie Gerassimov
Oct. 27, 2020

Our understanding of how long-chain fatty acids cross membranes is changing based on recent work by oratory at Boston University and others. Their research shows that unlike nutrients such as glucose or amino acids, which require a transporter, fatty acids can diffuse spontaneously through protein-free lipid bilayers and cells’ plasma membranes.

A in the Journal of Lipid Research by Anthony Jay and colleagues reveals how molecules previously thought to inhibit fatty acid transport specifically, including sulfosuccinimidyl oleate, or SSO, fit the diffusion model.

Control of fatty acid entry into cells is difficult to visualize. Researchers often have used fatty acid metabolites that become trapped in the cell to infer transport by plasma membrane proteins. The Hamilton lab has focused on distinguishing transmembrane movement from metabolism.

The lab made a that transport of fatty acids across a bilayer can be followed by pH changes. They combined a with phospholipid vesicles enclosing a pH-probe to measure absorption in real time. They showed that natural fatty acids can acquire a proton near the outer leaflet, leading to equilibrium between neutral and ionized forms. The net neutral fatty acid spontaneously diffuses across the bilayer and then releases the proton near the inner leaflet, reducing the internal pH. This energy-free diffusion has been termed the “flip-flop” mechanism.

JLR-schematic-762x423.jpg
James Hamilton/JLR
This schematic shows that (A) sulfosuccinimidyl oleate can flip-flop across the bilayer to enter cells, and (B) it can modify amino acids.

“Our studies also showed that all fatty acids studied … exhibit rapid flip-flop, and that this mechanism is reversible,” Hamilton said.

The researchers were excited by this finding but acknowledge that it does not exclude a role for proteins. Jay said, “If fatty acids can simply diffuse into cells, how could there be inhibitors of this transmembrane movement?”

The recent paper tests several proposed transport inhibitors, including the gold standard, SSO. Scientists had described SSO as a specific inhibitor of fatty acid entry into cells that acts on the fatty acid transporter CD36 without penetrating membranes. However, Hamilton’s team showed that SSO crosses membranes. Immunofluorescence using novel antibodies that bind SSO-linked fatty acids suggested that SSO modifies numerous proteins on the cell surface and interior, refuting the assumption of CD36 specificity.

The research informs nutritional considerations, Hamilton said. “Metabolism, and not the plasma membrane, controls the retention of fatty acids in cells, by trapping the fatty acids. Although membrane proteins may bind fatty acids or participate in metabolism, they cannot block diffusion in the surrounding bilayer.”

JLR-Res-617x460.jpg
James Hamilton/JLR
These image show immunofluorescence staining of amino acids modified with the fatty acid transporter CD36
and the fatty acid transport inhibitor sulfosuccinimidyl oleate. The insert on the right suggest that SSO staining is not
exclusive to CD36.

In fact, but CD36 increased the content of intercellular lipids.

For nutrition, Hamilton emphasized, “Healthy fatty acids such as omega 3 fatty acids need to enter cells readily, whereas unhealthy fatty acids, such as trans fatty acids, cannot be excluded from cells and need to be reduced in the diet.”

Hamilton’s lab is moving on to clinical trials using a high concentration of beneficial fatty acids to improve stroke and heart attack outcomes. Meanwhile, he recommends taking omega-3 supplements and eating more nuts.

Another interpretation

According to Maastricht University researchers Jan Glatz and Joost Luiken, the Hamilton lab’s results also could be interpreted as a step toward integration of the argument that fatty acids diffuse across the cell membrane and the view that the protein CD36 is required for fatty acid uptake. In a , Glatz and Luiken lay out their view that CD36 may be helpful but not necessary for lipid uptake.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Nathalie Gerassimov

Nathalie Gerassimov is a postdoctoral researcher at the Carnegie Institution of Washington department of embryology.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

How scientists identified a new neuromuscular disease
Feature

How scientists identified a new neuromuscular disease

Aug. 14, 2025

NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.

Unraveling cancer’s spaghetti proteins
Profile

Unraveling cancer’s spaghetti proteins

Aug. 13, 2025

MOSAIC scholar Katie Dunleavy investigates how Aurora kinase A shields oncogene c-MYC from degradation, using cutting-edge techniques to uncover new strategies targeting “undruggable†molecules.

How HCMV hijacks host cells — and beyond
Profile

How HCMV hijacks host cells — and beyond

Aug. 12, 2025

Ileana Cristea, an ASBMB Breakthroughs webinar speaker, presented her research on how viruses reprogram cell structure and metabolism to enhance infection and how these mechanisms might link viral infections to cancer and other diseases.

Understanding the lipid link to gene expression in the nucleus
Profile

Understanding the lipid link to gene expression in the nucleus

Aug. 11, 2025

Ray Blind, an ASBMB Breakthroughs speaker, presented his research on how lipids and sugars in the cell nucleus are involved in signaling and gene expression and how these pathways could be targeted to identify therapeutics for diseases like cancer.

Receptor antagonist reduces age-related bone loss in mice
Journal News

Receptor antagonist reduces age-related bone loss in mice

Aug. 6, 2025

Receptor antagonist reduces bone loss and promotes osteoblast activity in aging mice, highlighting its potential to treat osteoporosis. Read more about this recent JBC paper.

Engineered fusion protein targets kiwifruit pathogen
Journal News

Engineered fusion protein targets kiwifruit pathogen

Aug. 6, 2025

Synthetic protein selectively kills kiwifruit pathogen, offering a promising biocontrol strategy for agriculture. Read more about this recent JBC paper.